focus -WSS

focus

author：comprehensive 2025-10-01 02:16:27 - browse：973

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Pancreatic cancer early detection could be helped by AI

WSS

Male and female sex labels in research insufficient, scientists say

Pancreatic cancer early detection could be helped by AI

EPA limits use of carcinogenic gas for sterilizing medical devices

Merck CEO won’t testify in Senate, citing no expertise in drug prices

First U.S. drug developed to treat liver disease MASH is approved

Why scientists need input from humanists on sensitive research

hotspot

focus

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

State Dept. review finds Biden bears some blame for Afghanistan failures

Change Healthcare outage fallout shows need for new oversight

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare drug price negotiation legal challenge met with skepticism

23andMe had bad news about my health. I wish a person had delivered it

As AI in medicine takes off, can 'human in the loop' prevent harm?

Activists slam private health insurers over coverage restrictions

Syphilis numbers in the United States reach record heights

hotspot

Reconstructing family trees of blood cells may help predict disease

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Readout Newsletter: CAR

Syphilis numbers in the United States reach record heights

Boston's new lab space is opening empty

FDA advisers back CAR

knowledge

focus

Wikipedia

explore